Zacks Investment ResearchT3·42mo ago
SURI Simplify Propel Opportunities ETF
ETFETF quote, holdings, sector allocation, technicals, and options analytics. Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SURI
—
—
Key stats
About
Simplify Propel Opportunities ETF (SURI) ETF
No description available.
- Exchange
- ARCX
- Inception
- 2023-02-07
- Has Options
- No
Fund profile
holdings as of Jun 30, 2026SEC filingthrough Jun 2026flows, SEC filings
- Expense ratio
- 2.56% prospectus, filed May 18, 2026
- Assets
- $75M shares × price, Oct 9, 2026
- Trailing yield
- 15.80% paid quarterly
- Average daily volume
- $133K 30 sessions
- Holdings
- 39 top 10 are 155.1%
- Listed
- Feb 7, 2023 NYSE Arca
- Last fee change
- -1 bp filed May 18, 2026
Cost0
Liquidity4
Scale32
Diversification0
Moves with. Small caps over large (8% of its variance, beta 0.53); Bitcoin (4% of its variance, beta 0.06); US large-cap stocks (3% of its variance, beta 0.17). These factors explain 20% of its daily moves over the last year, so most of what drives this fund is something else.
Stated objective. Investment Objective: The Simplify Propel Opportunities ETF (the Fund or SURI) seeks long-term capital appreciation. (from the fund's prospectus)
All 39 holdingsFlow historySimilar fundsOverlap toolAll Small Cap Blend ETFs
Fund flows
through Jun 2026SEC filings- Jun 2026
- $0 latest reported month
- Latest 3 months
- −$2.6M −3.4% of assets
- Latest 12 months
- −$1.9M −2.5% of assets
View as a table
| Month | Net flow |
|---|---|
| Jun 2026 | $0 |
| May 2026 | −$1.1M |
| Apr 2026 | −$1.5M |
| Mar 2026 | −$1.4M |
| Feb 2026 | +$492K |
| Jan 2026 | +$167K |
| Dec 2025 | +$174K |
| Nov 2025 | $0 |
| Oct 2025 | +$325K |
| Sep 2025 | +$953K |
| Aug 2025 | $0 |
| Jul 2025 | $0 |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 42 months ago
Similar funds
Look-through: what the holdings say
weights as of Jun 30, 2026SEC filing- Holdings vs fair value
- +23.3% 73% under, 27% over · 93% covered
- Price / earnings
- — 45% loss-making · 89% covered
- Price / book · sales
- 3.0 · 0.2 revenue growth +17.7%
- Above 200-day average
- 74% 6% above 50-day · by weight
- Short interest
- 14.0% of float, weighted · 9.0 days to cover
- Insider buying
- 3% of weight had net insider buying, 90 days; 24% net selling
- 13F holders
- +9.3% change in shares held by institutions, latest quarter
- Reporting earnings
- 0.0% of weight in 7 days; 0.0% in 14
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
What changed in the portfolio
Mar 31, 2026 → Jun 30, 2026| Action | Holding | Weight before | Weight after | Shares vs flows |
|---|---|---|---|---|
| Increase | ACHVACHIEVE LIFE SCIENCES INC | 5.02% | 12.11% | +20.9% |
| Increase | MISTMILESTONE PHARMACEUTICALS INC | 2.58% | 5.81% | +122.3% |
| Exit | Oculis Holding AG | 2.56% | — | — |
| Exit | VRDNViridian Therapeutics Inc | 1.59% | — | — |
| Exit | VORVOR BIOPHARMA INC | 1.38% | — | — |
| Exit | TRVITrevi Therapeutics Inc | 1.13% | — | — |
| Increase | ARTVARTIVA BIOTHERAPEUTICS INC | 0.22% | 1.27% | +336.3% |
| New position | ACHIEVE LIFE SCIEN RTS | — | 0.97% | — |
| Exit | FDMT4D Molecular Therapeutics Inc | 0.95% | — | — |
| Decrease | CMPSCOMPASS PATHWAYS PLC | 1.27% | 2.09% | −28.1% |
1 new, 10 exited, 6 increased and 10 decreased between the fund's two latest holdings reports; turnover 112.1%. Full holdings and history
Under the hood
fiscal year to Jun 30, 2026SEC census- Authorized participants
- 3 active of 16 with agreements; top 3 did 100%
- Created · redeemed
- $4.1M · $6.0M over the fiscal year
- Redemptions in kind
- 0% creations 0% in kind
- Creation unit
- 10,000 shares
- Securities lending
- not authorized
- Diversification status
- Non-diversified may concentrate in fewer issuers
From the fund's annual census filing with the SEC. In-kind redemptions are what let an ETF shed appreciated securities without realising gains.
ETF Profile
holdings as of 2026-06-30
Holdings
38
AUM
$75.4M
Provider
Nport
Inception
2023-02-07
Exchange
ARCX
Data As Of
2026-06-30
Expense Ratio
2.56%
Dividend Yield
15.80%
Distribution
Quarterly
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-09-25 | 2026-09-30 | $0.6800 | CD |
| 2026-06-25 | 2026-06-30 | $0.6800 | CD |
| 2026-03-26 | 2026-03-31 | $0.6800 | CD |
| 2025-12-23 | 2025-12-31 | $0.6800 | CD |
| 2025-09-25 | 2025-09-30 | $0.6800 | CD |
| 2025-06-25 | 2025-06-30 | $0.6800 | CD |
Asset Allocation
Top Holdings
top 38 of 38 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | TREASURY BILL | 39.42% | Debt | US |
| PAGP | Plains GP Holdings LP | 32.36% | Equity (common) | US |
| — | DREYFUS TRSY OBLIG CASH M | 10.83% | Short-term investment | US |
| ACHV | Achieve Life Sciences Inc | 7.82% | Equity (common) | US |
| PHAT | Phathom Pharmaceuticals Inc | 7.10% | Equity (common) | US |
| VRDN | Viridian Therapeutics Inc | 4.28% | Equity (common) | US |
| MIST | Milestone Pharmaceuticals Inc | 4.04% | Equity (common) | CA |
| DCTH | Delcath Systems Inc | 3.50% | Equity (common) | US |
| ABEO | Abeona Therapeutics Inc | 3.50% | Equity (common) | US |
| CLDX | Celldex Therapeutics Inc | 3.07% | Equity (common) | US |
| CMPS | Compass Pathways Plc | 2.66% | Equity (common) | GB |
| — | Oculis Holding AG | 2.62% | Equity (common) | CH |
| — | WTS - ACHIEVE LIFE SCI | 2.53% | Equity (common) | US |
| KYTX | Kyverna Therapeutics Inc | 2.40% | Equity (common) | US |
| IVA | Inventiva SACA | 2.09% | Equity (common) | FR |
| NKTR | Nektar Therapeutics | 1.57% | Equity (common) | US |
| LONA | Athira Pharma Inc | 1.50% | Equity (common) | US |
| — | MILESTONE PHARMACE WTS | 1.27% | Equity (common) | US |
| — | TELESAT CANADA/TELESAT L | 1.06% | Debt | CA |
| SABS | SAB Biotherapeutics Inc | 1.03% | Equity (common) | US |
| RGNX | REGENXBIO Inc | 0.73% | Equity (common) | US |
| — | QUOIN PHARMACEUTIC WTS | 0.67% | Equity (common) | US |
| AKRO | Akero Therapeutics Inc | 0.57% | Equity (common) | US |
| ZVRA | Zevra Therapeutics Inc | 0.45% | Equity (common) | US |
| LENZ | LENZ Therapeutics Inc | 0.37% | Equity (common) | US |
| — | MILESTONE PHARMACE WTS | 0.36% | Equity (common) | US |
| — | QUOIN PHARMACEUTIC WTS | 0.25% | Equity (common) | US |
| KLRS | Kalaris Therapeutics Inc | 0.23% | Equity (common) | US |
| — | QUOIN PHARMACEUTIC WTS | 0.19% | Equity (common) | US |
| — | QUOIN PHARMACEUTIC WTS | 0.10% | Equity (common) | US |
| — | QUOIN PHARMACEUTIC WTS | 0.10% | Equity (common) | US |
| APLT | Applied Therapeutics Inc | 0.07% | Equity (common) | US |
| AARD | Aardvark Therapeutics Inc | 0.05% | Equity (common) | US |
| CVR | CHINOOK THERAPEUTICS INC CVR | 0.00% | Equity (common) | US |
| — | Eiger BioPharmaceuticals Inc | 0.00% | Equity (common) | US |
| — | JASPER THERAPEUTIC WTS | 0.00% | Equity (common) | US |
| — | WTS - TENAYA THERAPEUTICS | 0.00% | Equity (common) | US |
| — | MORGAN STANLEY & CO. LLC | -38.62% | Repurchase agreement | US |
Geographic Breakdown
Non-Equity Breakdown
Simplify Propel Opportunities ETF ·
NPORT-P period 2026-06-30
(filed 2026-08-24)
Net assets:
$77M
· 39 total positions
· equity 97.77%
· non-equity 2.70%
Non-equity holdings
— 3 positions,
2.70% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| US Treasury | 76.77% | $59.3M | 1 |
| Corporate | 1.16% | $895000 | 1 |
| Repurchase agreement | -75.22% | $-58112171 | 1 |
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | -0.09% | 10.95% | -1.53% | 3.11% |
| Feb | -3.13% | 22.78% | -5.33% | 3.91% | 4.56% |
| Mar | -17.64% | -3.89% | -6.47% | -10.19% | -9.55% |
| Apr | 9.47% | -12.92% | -1.91% | 8.54% | 0.79% |
| May | -4.45% | 1.73% | 1.43% | 3.93% | 0.66% |
| Jun | 2.59% | -2.15% | 4.80% | 2.82% | 2.01% |
| Jul | 1.33% | 9.10% | -0.20% | 1.02% | 2.81% |
| Aug | -2.09% | 2.43% | 9.41% | 11.37% | 5.28% |
| Sep | -6.86% | 2.22% | -1.76% | -13.64% | -5.01% |
| Oct | -5.40% | -0.80% | 8.88% | -0.90%* | 0.45% |
| Nov | 4.94% | -20.08% | 7.59% | -- | -2.52% |
| Dec | 3.14% | -18.89% | -7.14% | -- | -7.63% |
| Total | -19.00% | -24.93% | 19.53% | 2.63% | -5.44% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $18.08
SMA 50: $18.88
SMA 200: $17.57
Current: $17.22
EMA 12: $17.51
EMA 26: $18.12
MACD: -0.6133 | Signal: -0.0930
BEARISH
ADX (14): 36.44
TREND
+DI: 16.50
−DI: 40.59
Momentum Oscillators
RSI (14): 33.32
NEUTRAL
Stoch %K: 25.77
Stoch %D: 25.37
Williams %R: -69.18
Volume & Volatility
BB Upper: $19.95
BB Lower: $16.22
NEUTRAL
OBV: -181,095
Vol SMA 20: 9,571
Vol ROC: -79.80%
ATR: $0.43
True Range: $0.17
HV 20: 29.7%
HV 30: 26.2%
HV 60: 22.4%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-11T00:00:00 – 2026-10-09T00:00:00
AI Analysis
LLM Stock Analysis Report: SURI
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Consolidation phase in a range-bound market
- Bullish momentum signals tempered by neutral RSI reading
- Low volatility and correlation with the broader market
Primary Risks:
- Potential breakout above upper Bollinger Band ($18.42)
- Failure to break above SMA 50 ($17.65) could indicate continued consolidation
Investment Thesis: SURI is in a consolidation phase, with bullish momentum signals suggesting a potential breakout above its current range. However, the neutral RSI reading and low volatility suggest caution.
Recent News Sentiment Impact: The recent news headline about ETF areas had a NEUTRAL sentiment impact, which aligns with our overall assessment of a consolidation phase.
Technical Analysis
Trend Direction:
- Short-term: Neutral (range-bound)
- Medium-term: Bullish (moving averages trending upward)
- Long-term: Bearish (SMA 200 below current price)
Support/Resistance Levels:
- Lower Bollinger Band ($17.56) - potential support
- Upper Bollinger Band ($18.42) - potential resistance
Momentum Signals:
- RSI interpretation: Neutral (52.38)
- MACD signal: Bullish (0.14 above signal line)
- Bollinger Bands position: Squeeze
Volume Analysis:
- Volume SMA 20: 3361.45
- On-Balance Volume (OBV): -111125.61 (indicating bearish momentum)
- Volume Rate of Change: -50.84% (indicating decreasing volume)
News & Sentiment Analysis
Recent Headlines Summary:
- One neutral news headline about ETF areas
Sentiment Assessment:
- Aggregate sentiment: NEUTRAL
- No significant news catalysts or events in the near term
Catalyst Identification:
- No upcoming earnings dates or major product launches scheduled
- Regulatory changes or unexpected news could impact the stock's price
Market Narrative:
- The neutral RSI reading and low volatility suggest a market environment where stocks are trading within established ranges, rather than experiencing significant moves.
Risk & Volatility Assessment
Beta Interpretation: Low-risk (beta 0.67)
Volatility Regime: Low-volatility regime compared to historical levels
Options Market Signals:
- IV rank: N/A (implied volatility too low to generate a meaningful signal)
- Put/call ratios: N/A
- Unusual activity: N/A
Downside Protection:
- Support level at the lower Bollinger Band ($17.56) - potential stop-loss level
Market Context & Positioning
Sector Performance:
- Relative strength within its sector
Institutional Activity:
- Volume patterns suggesting institutional interest is low
Correlation Analysis:
- Correlation with the broader market: 0.36 (low)
Relative Valuation:
- SURI's relative valuation is neutral, with no significant deviation from its trading range.
Key Levels & Action Items
Critical Price Levels:
- Lower Bollinger Band ($17.56) - potential support
- Upper Bollinger Band ($18.42) - potential resistance
Breakout/Breakdown Levels:
- SMA 50 ($17.65) - potential breakout level
Time-Sensitive Catalysts:
- No significant events or announcements scheduled in the near term
Risk Management:
- Stop-loss levels: Lower Bollinger Band ($17.56)
- Position sizing considerations: Conservative approach recommended due to low volatility and neutral RSI reading.
By following this analysis framework, we have provided a comprehensive report on SURI's technical analysis, news and sentiment analysis, risk and volatility assessment, market context, and positioning.
Generated
News
All SURI news →
SURI Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 0.5959
Alpha: -1.14%
Correlation: 0.3315
R-Squared: 11.0%
Stock Volatility: 23.4%
Market Volatility: 13.0%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
SURI Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
SURI Constituent Performance
Click any bar to view the full quote for that stock.
SURI Constituents (22 of 22)
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| PAGP | Plains GP Holdings LP | 32.36% | $26.62 | +0.19% | +2.15% | -4.89% |
| ACHV | Achieve Life Sciences Inc | 7.82% | $7.41 | +3.06% | +2.35% | +4.96% |
| PHAT | Phathom Pharmaceuticals Inc | 7.10% | $7.25 | +1.68% | +4.77% | -13.28% |
| VRDN | Viridian Therapeutics Inc | 4.28% | $18.66 | +1.74% | -3.81% | -12.15% |
| MIST | Milestone Pharmaceuticals Inc | 4.04% | $0.77 | +7.43% | -5.52% | -21.95% |
| DCTH | Delcath Systems Inc | 3.50% | $15.36 | +2.13% | +1.52% | -3.46% |
| ABEO | Abeona Therapeutics Inc | 3.50% | $4.94 | -0.40% | -1.79% | -8.77% |
| CLDX | Celldex Therapeutics Inc | 3.07% | $29.89 | +2.01% | -5.56% | -19.00% |
| CMPS | Compass Pathways Plc | 2.66% | $12 | +4.62% | +0.84% | -16.38% |
| KYTX | Kyverna Therapeutics Inc | 2.40% | $6.39 | +3.40% | +2.73% | -11.98% |
| IVA | Inventiva SACA | 2.09% | $3.16 | -4.82% | -11.24% | -21.39% |
| NKTR | Nektar Therapeutics | 1.57% | $41.17 | +0.91% | -5.53% | -40.98% |
| LONA | Athira Pharma Inc | 1.50% | $5.75 | +0.00% | +19.29% | -16.91% |
| SABS | SAB Biotherapeutics Inc | 1.03% | $2.98 | +3.11% | +0.00% | -12.61% |
| RGNX | REGENXBIO Inc | 0.73% | $8.07 | -0.25% | +8.61% | -5.39% |
| AKRO | Akero Therapeutics Inc | 0.57% | $54.65 | +0.18% | +0.39% | +1.13% |
| ZVRA | Zevra Therapeutics Inc | 0.45% | $11.39 | +3.55% | +14.01% | -5.16% |
| LENZ | LENZ Therapeutics Inc | 0.37% | $3.65 | +3.26% | +1.82% | -19.36% |
| KLRS | Kalaris Therapeutics Inc | 0.23% | $2.36 | -5.60% | -12.59% | -30.18% |
| APLT | Applied Therapeutics Inc | 0.07% | $0.1 | +0.19% | +6.96% | +0.29% |
| AARD | Aardvark Therapeutics Inc | 0.05% | $4.76 | +1.06% | -4.61% | -7.21% |
| CVR | CHINOOK THERAPEUTICS INC CVR | 0.00% | $11.2 | -3.24% | +-0.00% | +9.16% |